🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. Naltrexone implant, 14.4 grams

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule active

    1 trial

  2. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Neoplasms

    phase 1 small molecule completed

    1 trial

  3. NeuroRegen scaffold with BMMCs or MSCs transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injury

    phase 1 mab active

    1 trial

  4. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  5. ORIC-101

    Topiloric/Uriadec

    Prostatic Neoplasms

    phase 1 small molecule terminated

    1 trial

  6. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  7. Outpatient MST/OPTION-A

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 1 other completed

    1 trial

  8. PNEUMOSTEM®

    Samsung Bioepis NL B.V.

    Pulmonary Arterial Hypertension (PAH)

    phase 1 mab active

    1 trial

  9. Part A: Dose Escalation of Cantrixil

    KAZIA THERAPEUTICS LTD

    Ovarian Neoplasms

    phase 1 small molecule completed

    1 trial

  10. Pazopanib

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 1 small molecule completed

    1 trial

  11. Pevonedistat

    Takeda

    Advanced Solid Tumors, Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  12. Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

  13. Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  14. Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

    The George Institute

    Non-small cell lung cancer (NSCLC)

    phase 1 other active

    1 trial

  15. RO5503781

    Hoffmann-La Roche

    Neoplasms

    phase 1 small molecule completed

    1 trial

  16. Refametinib (BAY86-9766)

    Bayer HealthCare AG

    Neoplasms

    phase 1 small molecule completed

    1 trial

  17. SIG001

    The First People's Hospital of Lianyungang

    Neoplams

    phase 1 mab active

    1 trial

  18. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  19. TAK-164

    Takeda

    Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

    phase 1 small molecule terminated

    1 trial

  20. TAK-931

    Takeda

    Nonhematologic Neoplasms, Advanced

    phase 1 small molecule completed

    1 trial

  21. TAK-931 PIC

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  22. TAK-935

    Takeda

    Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

    phase 1 small molecule completed

    1 trial

  23. TMS (MagVenture MagPro 100 with MagOption)

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 other active

    1 trial

  24. TRIN2755

    BRIGHT MINDS BIOSCIENCES INC.

    Neoplasms

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources